Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinwang Duan

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Rheumatology (Oxford, England)|July 3, 2023
Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trialDong Xu, Jianmin Fang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases|April 17, 2025
The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositisXinzhuang Yang, Chen Yu, Xiuling Zhang, et al.
Rheumatology and Immunology Research|April 13, 2026
Community-based epidemiological study on the prevalence and health status of Spondyloarthritis in residents of Wuyuan County, China, 2023Shichao Yu, Xiuling Zhang, Zhijie Liu, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Chinese Medical Journal|April 10, 2023
Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR)Fan Yang, Chaofan Lu, Huilan Liu, et al.
Clinical Rheumatology|June 7, 2025
Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendationsWei Bai, Yinli Gui, Jia Liu, et al.
International Journal of Rheumatic Diseases|January 18, 2025
Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate-To-Severe Disease Activity - A Multicenter Cohort Study of Treatment Strategies and OutcomesYafang Deng, Lin Qiao, Hongbin Li, et al.
International Journal of Rheumatic Diseases|July 10, 2023
Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritisChaofan Lu, Fan Yang, Huilan Liu, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Rheumatology (Oxford, England)|July 3, 2023
Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trialDong Xu, Jianmin Fang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases|April 17, 2025
The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositisXinzhuang Yang, Chen Yu, Xiuling Zhang, et al.
Rheumatology and Immunology Research|April 13, 2026
Community-based epidemiological study on the prevalence and health status of Spondyloarthritis in residents of Wuyuan County, China, 2023Shichao Yu, Xiuling Zhang, Zhijie Liu, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Chinese Medical Journal|April 10, 2023
Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR)Fan Yang, Chaofan Lu, Huilan Liu, et al.
Clinical Rheumatology|June 7, 2025
Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendationsWei Bai, Yinli Gui, Jia Liu, et al.
International Journal of Rheumatic Diseases|January 18, 2025
Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate-To-Severe Disease Activity - A Multicenter Cohort Study of Treatment Strategies and OutcomesYafang Deng, Lin Qiao, Hongbin Li, et al.
International Journal of Rheumatic Diseases|July 10, 2023
Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritisChaofan Lu, Fan Yang, Huilan Liu, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Pageof 8